New Rule: Matt Harman Talks About Employer Interest in Biosimilar Promotion
March 26th 2020Matt Harman talks about employer interest in biosimilar promotion and how the FDA's new biologics pathway change will affect interest levels, during the World Biosimilar Congress USA 2020 at the Festival of Biologics USA in San Diego, California.
Wayne Winegarden, PhD, Explains the Impact of the BPCIA Regulatory Change
March 24th 2020Wayne Winegarden, PhD, talked about the issues and benefits of the FDA's switch to a biologics regulatory pathway for certain products, especially insulin, during the World Biosimilar Congress USA 2020 at the Festival of Biologics USA in San Diego, California.
Sheila Frame Discusses Biosimilar Policy Developments and Market Impact
March 17th 2020Sheila Frame, the vice president of marketing, market access, and patient services at Sandoz, discusses US biosimilar policies in development and the impact they will have on the market at the World Biosimilar Congress 2020 at the Festival of Biologics USA in San Diego, California.
Dr Lindsey Roeker: Adding Rituximab to Venetoclax in Patients With CLL
February 3rd 2020Lindsey Roeker, MD, clinical fellow at Memorial Sloan Kettering Cancer Center, discusses adding rituximab to venetoclax to allow for a 2-year fixed-duration treatment schedule for patients with chronic lymphocytic leukemia (CLL).
Elaine Husni, MD, MPH: Biosimilars and Cost Savings for Patients
December 31st 2019Elaine Husni, MD, MPH, vice chair and director of the Arthritis and Musculoskeletal Center in the Orthopedic and Rheumatologic Institute at the Cleveland Clinic, discusses whether biosimilars are generating cost savings for patients with inflammatory diseases.
Jeffrey Patton, MD: Adopting Biosimilar Trastuzumab, Bevacizumab, and Rituximab in the Clinic
November 25th 2019Jeffrey Patton, MD, chief executive officer of Tennessee Oncology and president of physician services for OneOncology, discusses adoption of biosimilar trastuzumab, bevacizumab, and rituximab.
Cate Lockhart, PharmD, PhD: Challenges With Large-Scale Comparative Effectiveness Research
November 22nd 2019Cate Lockhart, PharmD, PhD, executive director of the Biologics and Biosimilars Collective Intelligence Consortium (BBCIC), discusses the challenges inherent in conducting large-scale comparative effectiveness research on biologics and biosimilars.